ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Tocilizmab (Anti-IL-6R) Treatment (TCZ-Rx) Reduced Total IgG Levels Including Anti-HLA IgG: Analysis of IgG Subclasses (IgG1-IgG4) and Anti-HLA IgG Subclasses Show Similar Reductions in All Subclasses from Patients with DSA+ Chronic Antibody-Mediated Rejection (CABMR).

B.-H. Shin,1 M. Everly,2 J. Choi,1 S. Ge,1 A. Petrosyan,1 A. Vo,1 S. Jordan,1 M. Toyoda.1

1Transplant Immunology Laboratory and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
2Terasaki Foundation Laboratory, Los Angeles

Meeting: 2017 American Transplant Congress

Abstract number: B75

Keywords: Antibodies, HLA antibodies, Immunoglobulins (Ig), Rejection

Session Information

Date: Sunday, April 30, 2017

Session Name: Poster Session B: Antibody Mediated Rejection in Kidney Transplant Recipients II

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Related Abstracts
  • Immunoglobulin G Donor-Specific Anti-HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury
  • The Effect of Tocilizmab Treatment (TCZ-Rx) on IgG Subclasses in HLA-sensitized (HS) Kidney Transplant Patients Treated with TCZ.

Background: DSA+ CABMR constitutes the major cause for renal allograft loss in the U.S. Currently there are no approved therapies. We have reported TCZ use for pre-Tx desensitization (DES) and CABMR Rx. Complement- (CDC) and Ab-dependent cellular cytotoxicity (ADCC) are mechanisms for ABMR mediated primarily by IgG1&3 subclasses. We previously showed that TCZ-Rx reduced all 4 IgG subclasses, but reduction of IgG3 elevated pre-TCZ was most significant. Here we determined if TCZ-Rx reduced IgG1-4 subclasses and anti-HLA IgG subclasses. Methods: Archived plasma obtained pre- & post-TCZ-Rx (8mg/kg, 6x, monthly) from 15 Pts were tested for total IgG & IgG1-4 by ELISA, and anti-HLA total IgG, IgG3&4 by luminex. Anti-HLA total IgG (class I & II) levels were expressed as score (score 10, 5, 2 & 0 for SFI>200K, 100K-200K, <100K & 0, respectively, are given to each detected Ab), and IgG3&4 as MFI. The sum of the scores and MFIs were the final levels for serum w/ multiple Abs. Pre-TCZ IL-6 levels were also measured by luminex. Results: Total IgG, IgG1-4, and anti-HLA total IgG, DSA & IgG3 were significantly decreased post-TCZ (Table 1). No DSA was IgG3 subclass. Anti-HLA IgG4 also decreased, but not significantly. There was no correlation between pre-TCZ IL-6 and all types of IgGs tested. Conclusions: TCZ-Rx reduces total IgG, all 4 IgG subclass, anti-HLA total IgG, DSA, IgG3&4 subclass levels, indicating that IgG reduction by TCZ is non-specific via its anti-B cell property. This suggests that TCZ could reduce both CDC and ADCC-mediated ABMR.

Pre-TCZ post-TCZ
Total IgG (mg/ml) 13.0±2.5 10.8±3.0*
IgG1 ([mu]g/ml) 9.5±5.2 6.9±4.6*
IgG2 ([mu]g/ml) 4.0±2.4 2.4±1.0*
IgG3 ([mu]g/ml) 1.3±1.4 0.7±0.5*
IgG4 ([mu]g/ml) 0.3±0.2 0.2±0.2#
Anti-HLA-IgG (score) 99±79 71±71*
DSA (score) 10.0±8.7 4.8±6.8*
IgG3 (MFI, x1000) 9.5±27.9 2.2±4.4*
IgG4 (MFI, x1000) 2.4±7.2 0.5±1.3

*p<0.0.5 & 0.05<#P<0.1 vs. pre-TCZ.

CITATION INFORMATION: Shin B.-H, Everly M, Choi J, Ge S, Petrosyan A, Vo A, Jordan S, Toyoda M. Tocilizmab (Anti-IL-6R) Treatment (TCZ-Rx) Reduced Total IgG Levels Including Anti-HLA IgG: Analysis of IgG Subclasses (IgG1-IgG4) and Anti-HLA IgG Subclasses Show Similar Reductions in All Subclasses from Patients with DSA+ Chronic Antibody-Mediated Rejection (CABMR). Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Shin B-H, Everly M, Choi J, Ge S, Petrosyan A, Vo A, Jordan S, Toyoda M. Tocilizmab (Anti-IL-6R) Treatment (TCZ-Rx) Reduced Total IgG Levels Including Anti-HLA IgG: Analysis of IgG Subclasses (IgG1-IgG4) and Anti-HLA IgG Subclasses Show Similar Reductions in All Subclasses from Patients with DSA+ Chronic Antibody-Mediated Rejection (CABMR). [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/tocilizmab-anti-il-6r-treatment-tcz-rx-reduced-total-igg-levels-including-anti-hla-igg-analysis-of-igg-subclasses-igg1-igg4-and-anti-hla-igg-subclasses-show-similar-reductions-in-all-subclasses/. Accessed January 25, 2021.

« Back to 2017 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.